

CITATION REPORT

List of articles citing

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

DOI: 10.1093/rheumatology/keg072
Rheumatology, 2003, 42, 244-57.

Source: <https://exaly.com/paper-pdf/35699743/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
754	A comparison of regulatory cells in spinal fluid and blood in patients with multiple sclerosis and other neurologic diseases. 1990 , 40, 1785-90		9
753	The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care. 2003 , 5, 336-40		
752	A disease activity score for polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1279-83	2.4	92
751	TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 4-10	2.4	90
750	Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63 Suppl 2, ii32-ii39	2.4	28
749	Patients with rheumatoid arthritis in clinical care. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 221-5	2.4	46
748	Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63 Suppl 2, ii2-ii12	2.4	41
747	Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 144-8	2.4	33
746	Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. 2004 , 57, 790-7		17
745	Leflunomide in active rheumatoid arthritis: a prospective study in daily practice. 2004 , 58, 201-8		18
744	L'valuation clinique et biologique dans la prise en charge de personnes souffrant de polyarthrite rhumatoïde: établissement de recommandations pour la pratique clinique à partir de données de la littérature et d'opinions d'experts (Rencontres d'experts en rhumatologie). 2004 , 71, S127-S136		2
743	Quantitative measures and indices to assess rheumatoid arthritis in clinical trials and clinical care. 2004 , 30, 725-51, vi		13
742	Measurement of global functional performance in patients with rheumatoid arthritis using rheumatology function tests. 2004 , 6, R315-25		24
741	Quels critères le rhumatologue doit-il connaître et utiliser pour suivre une polyarthrite rhumatoïde?. 2005 , 72, 207-212		
740	Spécificités méthodologiques de la recherche clinique dans la polyarthrite rhumatoïde. 2005 , 72, 337-345		
739	Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. 2005 , 28, 239-48		55
738	Selecting criteria for monitoring patients with rheumatoid arthritis. 2005 , 72, 129-34		10

737	Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion. 2005 , 72, 222-8		37
736	How to assess early rheumatoid arthritis in daily clinical practice. 2005 , 19, 73-89		10
735	Therapeutic strategies in early rheumatoid arthritis. 2005 , 19, 163-77		55
734	Disease activity measurement of rheumatoid arthritis: Comparison of the simplified disease activity index (SDAI) and the disease activity score including 28 joints (DAS28) in daily routine. 2005 , 53, 56-60		51
733	Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. 2005 , 52, 2625-36		337
732	The need for new classification criteria for rheumatoid arthritis. 2005 , 52, 3333-6		37
731	The patient's perspective and rheumatoid arthritis disease activity indexes. 2005 , 44, 360-5		37
730	Panel discussion on B cells and rituximab: mechanistic aspects, efficacy and safety in rheumatoid arthritis and non-Hodgkin's lymphoma. <i>Rheumatology</i> , 2005 , 44 Suppl 2, ii18-ii20	3.9	6
729	Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 4, iv2-14	2.4	92
728	Response criteria for rheumatoid arthritis in clinical practice: how useful are they?. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 1186-9	2.4	21
727	Biological drug use: US perspectives on indications and monitoring. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64 Suppl 4, iv18-23	2.4	37
726	DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment. <i>Arthritis Research and Therapy</i> , 2005 , 7, R1063-71	5.7	63
725	Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. 2005 , 7, R796-806		640
724	EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 34-45	2.4	508
723	Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes. 2006 , 35, 441-6		31
722	The definition and measurement of disease modification in inflammatory rheumatic diseases. 2006 , 32, 9-44, vii		87
721	Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). <i>Rheumatology</i> , 2006 , 45, 649-52	3.9	22
720	[Clinical outcome measures in hand- and finger joint osteoarthritis from the patient perspective]. 2006 , 65, 139-43		4

719	[Measuring disease activity for rheumatoid arthritis]. 2006 , 65, 93-6, 98-102		3
718	Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. 2006 , 54, 702-10		336
717	The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. 2006 , 54, 377-8; author reply 378		11
716	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. 2006 , 54, 2784-92		205
715	Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. 2006 , 55, 884-91		11
714	Comparison of treatment-response criteria for juvenile idiopathic arthritis. 2006 , 2, 466-7		
713	Rheumatoid Arthritis and the Skin. 2006 , 161-183		
712	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65 Suppl 3, iii2-15	2.4	50
711	The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. <i>Rheumatology</i> , 2006 , 45, 1133-9	3.9	40
710	Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials. 2006 , 2, 611-8		22
709	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006 , 16, 381-388	3.3	16
708	The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1038-42	2.4	53
707	Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1633-40	2.4	23
706	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66 Suppl 3, iii2-22	2.4	85
705	New therapies for treatment of rheumatoid arthritis. 2007 , 370, 1861-74		706
704	[How do we evaluate an inadequate response in a patient with rheumatoid arthritis in the clinical praxis P?]. 2007 , 3, 38-44		6
703	Remission by composite scores in rheumatoid arthritis: are ankles and feet important?. <i>Arthritis Research and Therapy</i> , 2007 , 9, R72	5.7	28
702	Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. <i>Modern Rheumatology</i> , 2007 , 17, 403-408	3.3	31

701	An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. <i>Rheumatology</i> , 2008 , 47, 345-9	3.9	90
700	How Do We Evaluate an Inadequate Response in a Patient With Rheumatoid Arthritis in the Clinical Praxis?. 2007 , 3, 38-44		
699	Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. 2007 , 56, 2135-42		98
698	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. 2007 , 56, 3226-35		181
697	Management of established rheumatoid arthritis with an emphasis on pharmacotherapy. 2007 , 21, 43-57		4
696	The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. 2007 , 21, 663-75		100
695	A proposed continuous quality improvement approach to assessment and management of patients with rheumatoid arthritis without formal joint counts, based on quantitative routine assessment of patient index data (RAPID) scores on a multidimensional health assessment questionnaire (MDHAQ). 2007 , 21, 789-804		48
694	Established rheumatoid arthritis: clinical assessments. 2007 , 21, 807-25		11
693	Characterization of valvular heart disease in rheumatoid arthritis by transesophageal echocardiography and clinical correlates. 2007 , 100, 496-502		34
692	Update on indices of disease activity in systemic sclerosis. 2007 , 37, 93-8		48
691	Rheumatoid arthritis in the United Arab Emirates. 2008 , 27, 739-42		24
690	The burden of rheumatoid arthritis and access to treatment: a medical overview. 2008 , 8 Suppl 2, S39-47		16
689	Development and validation of a patient-based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice. 2008 , 59, 192-9		29
688	Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. 2008 , 59, 884-91		25
687	The importance of reporting disease activity states in rheumatoid arthritis clinical trials. 2008 , 58, 2622-31		39
686	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. 2008 , 59, 1371-7		159
685	Les autoanticorps n'influent pas le développement des plaques d'athérome dans la polyarthrite rhumatoïde. 2008 , 75, 596-601		
684	Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis. 2008 , 75, 416-21		25

683	SDAI/CDAI levels in rheumatoid arthritis patients are highly dependent on patient's pain perception and gender. 2008 , 37, 410-3		16
682	Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1153-8	2.4	48
681	Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1360-4	2.4	132
680	Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 967-71	2.4	66
679	Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1365-73	2.4	13
678	Monitoring disease activity in rheumatoid arthritis: an imperative. 2008 , 3, 99-102		
677	Measures of Disease Activity in Rheumatoid Arthritis: A Clinicians Guide. 2008 , 4, 259-265		14
676	Activity assessments in rheumatoid arthritis. 2008 , 20, 306-13		27
675	How to assess patients with rheumatoid arthritis and concomitant fibromyalgia?. <i>Journal of Rheumatology</i> , 2009 , 36, 9-11	4.1	12
674	NUCLEAR (SCINTIGRAPHIC) METHODS AND FDG-PET IN RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS. 2009 , 138-149		3
673	Effect of the human leukocyte antigen HLA-DRB1 and anti-cyclic citrullinated peptide on the outcome of rheumatoid arthritis patients. 2009 , 42, 831-8		8
672	Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 1606-10	4.1	74
671	Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 972-5	2.4	63
670	Monitoring anti-TNFalpha treatment in rheumatoid arthritis: responsiveness of magnetic resonance imaging and ultrasonography of the dominant wrist joint compared with conventional measures of disease activity and structural damage. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1572-9	2.4	72
669	Residual minimal disease activity in rheumatoid arthritis: a simple definition through an in-depth statistical analysis of the major outcome. <i>Rheumatology</i> , 2009 , 48, 1242-6	3.9	6
668	Development of quality indicators for monitoring of the disease course in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1805-10	2.4	28
667	Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: an observational cohort study from southern Sweden. <i>Journal of Rheumatology</i> , 2009 , 36, 517-21	4.1	17
666	Assessment and management of rheumatoid arthritis. 2009 , 82, 2-10		4

665	Inflammatory arthritis: an overview for primary care physicians. 2009 , 121, 148-62		4
664	Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. <i>Journal of Rheumatology</i> , 2009 , 36, 2435-42	4.1	51
663	Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. <i>Rheumatology</i> , 2009 , 48, 1575-80	3.9	58
662	"KISS"--embracing routine patient assessment. <i>Journal of Rheumatology</i> , 2009 , 36, 1096-8	4.1	1
661	Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 823-7	2.4	159
660	Disease activity level, remission and response in established rheumatoid arthritis: performance of various criteria sets in an observational cohort, treated with anti-TNF agents. 2009 , 10, 41		33
659	Assessing adequate treatment response in patients with rheumatoid arthritis. 2009 , 31, 1219-31		7
658	Developing outcome measures for paediatric rheumatic diseases. 2009 , 23, 609-24		35
657	Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline. 2009 , 61, 313-20		53
656	Physician ability to assess rheumatoid arthritis disease activity using an electronic medical record-based disease activity calculator. 2009 , 61, 495-500		11
655	Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. 2009 , 60, 1242-9		99
654	Development and validation of a composite disease activity score for juvenile idiopathic arthritis. 2009 , 61, 658-66		424
653	The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis. 2009 , 60, 1624-31		50
652	Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis. 2009 , 60, 3776-83		9
651	Autoantibodies and other serological markers in rheumatoid arthritis: predictors of disease activity?. 2009 , 28, 1127-34		15
650	Évaluation de l'activité de la polyarthrite rhumatoïde, quel indice composite faut-il utiliser ?. 2009 , 76, S3-S10		1
649	Use of a night-time hand positioning splint reduced pain, improved grip and pinch strength, upper limb function and functional status in patients with rheumatoid arthritis. 2009 , 56, 211-2		
648	Erratum. 2009 , 60, 1249-1249		3

647	Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1680-5	2.4	145
646	A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. 2009 , 61, S1-S46		28
645	Pain in arthritis. 2009 , 3, 123-127		5
644	The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. 2009 , 35, 759-72, viii		35
643	Outcome measures in inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2009 , 11, 244	5.7	33
642	Developments in the clinical understanding of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009 , 11, 204	5.7	43
641	Comparison of three rheumatoid arthritis disease activity scores in clinical routine. 2009 , 38, 336-41		24
640	Simplified Disease Activity Index as an index of disease activity in patients with rheumatoid arthritis: a comparison with DAS28. 2009 , 4, 11-14		6
639	Remission in rheumatoid arthritis: Which definition to use in the clinic?. 2009 , 4, 15-19		1
638	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. 2009 , 374, 210-21		416
637	Artritis reumatoide (II). 2009 , 10, 1927-1932		
636	Polymorphisms within the folate pathway predict folate concentrations but are not associated with disease activity in rheumatoid arthritis patients on methotrexate. 2010 , 20, 367-76		51
635	1. Rheumatoid Arthritis. 2010 , 99, 2392-2400		2
634	[Health-related quality of life (HRQoL) in rheumatoid arthritis]. 2010 , 69, 198-202		1
633	State-of-the-art: rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1898-906	2.4	215
632	The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. 2010 , 29, 473-7		17
631	Performance of rheumatoid arthritis disease activity measures and juvenile arthritis disease activity scores in polyarticular-course juvenile idiopathic arthritis: Analysis of their ability to classify the American College of Rheumatology pediatric measures of response and the preliminary criteria for flare and inactive disease. 2010 , 62, 1095-102		17
630	Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. 2010 , 62, 1481-8		28

629	Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. 2010 , 62, 359-68		64
628	Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis. 2010 , 43, 1309-14		36
627	Quantitation of glucocorticoid receptor alpha and NF- κ B pathway mRNA and its correlation with disease activity in rheumatoid arthritis patients. 2010 , 9, 2300-10		9
626	Disease activity composite indices in patients with rheumatoid arthritis and concomitant fibromyalgia. <i>Journal of Rheumatology</i> , 2010 , 37, 468; author reply 469	4.1	10
625	A modified rheumatoid arthritis disease activity score without acute-phase reactants (mDAS28) for epidemiological research. <i>Journal of Rheumatology</i> , 2010 , 37, 1607-14	4.1	12
624	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 638-643	2.4	168
623	Correlation of Fatigue with Clinical Parameters and Quality of Life in Rheumatoid Arthritis. 2010 , 25, 63-67		6
622	Early referral to the rheumatologist for early arthritis patients: evidence for suboptimal care. Results from the ESPOIR cohort. <i>Rheumatology</i> , 2010 , 49, 147-55	3.9	26
621	The responsiveness of joint counts, patient-reported measures and proposed composite scores in hand osteoarthritis: analyses from a placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1436-40	2.4	14
620	How to improve DAS28 use in daily clinical practice?--a pilot study of a nurse-led intervention. <i>Rheumatology</i> , 2010 , 49, 741-8	3.9	21
619	Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 536-41	2.4	90
618	Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. <i>Rheumatology</i> , 2010 , 49, 683-90	3.9	109
617	Patient-derived joint counts are a potential alternative for determining Disease Activity Score. <i>Journal of Rheumatology</i> , 2010 , 37, 1035-41	4.1	21
616	Improving the routine management of rheumatoid arthritis: the value of tight control. <i>Journal of Rheumatology</i> , 2010 , 37, 1570-8	4.1	23
615	Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 546-9	2.4	57
614	Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. <i>Modern Rheumatology</i> , 2010 , 20, 539-547	3.3	18
613	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 575-8	2.4	36
612	Anti-tumor necrosis factor therapies in immune-mediated rheumatic diseases. Other observations from the clinic. 2010 , 85, 53-62		3

611	How should rheumatoid arthritis disease activity be measured today and in the future in clinical care?. 2010 , 36, 243-57		10
610	[Influence of gender on treatment response in a cohort of patients with early rheumatoid arthritis in the area 2 of Madrid]. 2010 , 6, 134-40		6
609	[Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis]. 2010 , 6, 23-36		62
608	Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. 2010 , 6, 23-36		0
607	Influence of gender on treatment response in a cohort of patients with early rheumatoid arthritis in the area 2 of Madrid. 2010 , 6, 134-140		
606	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1441-7	2.4	182
605	A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1349-51	2.4	61
604	Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1058-64	2.4	79
603	Management of Rheumatoid Arthritis. 2010 , 17-26		
602	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 631-7	2.4	1300
601	The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1039-46	2.4	129
600	Review of treatment response in rheumatoid arthritis: assessment of heterogeneity. 2011 , 27, 697-711		13
599	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 404-13	2.4	518
598	Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2011 , 13, R78	5.7	64
597	Comparative study of indices of activity evaluation in rheumatoid arthritis. 2011 , 54, 421-8		8
596	Oral hygiene and periodontal status in a group of patients with rheumatoid arthritis. 2011 , 6, 111-115		4
595	Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 469-75	2.4	128
594	Managed Care Strategies for Improving Patient Outcomes in Rheumatoid Arthritis. 2011 , 17, 1-29		

593	Consenso da Sociedade Brasileira de Reumatologia 2011 para o diagnóstico e avaliação inicial da artrite reumatoide. 2011 , 51, 207-219		15
592	GISEA: an Italian biological agents registry in rheumatology. 2011 , 63, 155-64		19
591	[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]. 2006 , 58, 22-5		3
590	Assessment of disease activity and treatment outcomes in rheumatoid arthritis. 2011 , 17, S09-13		24
589	Treating rheumatoid arthritis to target: the patient version of the international recommendations. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 891-5	2.4	60
588	[The cutting-edge of medicine: paradigm shift of diagnosis and treatment of rheumatoid arthritis]. 2011 , 100, 1978-86		
587	1858 C/T polymorphism of the protein tyrosine phosphatase nonreceptor 22 gene and rheumatoid arthritis risk in europeans: a meta-analysis. 2011 , 42, 698-702		9
586	Established rheumatoid arthritis: rationale for best practice: physicians' perspective of how to realise tight control in clinical practice. 2011 , 25, 509-21		14
585	Current smoking status is associated to a non-ACR 50 response in early rheumatoid arthritis. A cohort study. 2011 , 30, 1589-93		29
584	Monitoring anti-interleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger. 2011 , 40, 745-55		29
583	Ultrasound in rheumatoid arthritis: volar versus dorsal synovitis evaluation and scoring. 2011 , 12, 124		32
582	Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score II (PASII). <i>Qualitative Assessment of</i>		159
581	Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in umatoid rheumatoid arthritis: the role of acute-phase reactants. 2011 , 63, 43-52		110
580	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. 2011 , 63, 573-86		520
579	Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. 2011 , 63, 3702-11		99
578	Clinical composite measures of disease activity for diagnosis and followup of undifferentiated peripheral inflammatory arthritis: a systematic review. 2011 , 87, 48-53		1
577	Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. 2011 , 27, 315-25		12
576	Levels of plasma fibrinogen are elevated in well-controlled rheumatoid arthritis. <i>Rheumatology</i> , 2011 , 50, 1458-65	3.9	28

575	An observational study of tocilizumab and TNF- α inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. <i>Rheumatology</i> , 2011 , 50, 2093-9	3.9	20
574	Use of clinical disease activity index score for assessment of disease activity in rheumatoid arthritis patients: an Indian experience. 2011 , 2011, 146398		14
573	Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 2103-10	2.4	16
572	50th volume--60 years. A golden year. <i>Rheumatology</i> , 2011 , 50, 1-3	3.9	7
571	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 996-1002	2.4	54
570	Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1815-21	2.4	77
569	Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 733-9	2.4	115
568	Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 792-8	2.4	144
567	Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 935-42	2.4	180
566	Comparison of composite disease activity indices for rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011 , 21, 134-143	3.3	15
565	Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1316-21	2.4	136
564	Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study. <i>Rheumatology</i> , 2012 , 51, 2164-9	3.9	21
563	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 799-803	2.4	76
562	Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria. <i>Rheumatology</i> , 2012 , 51, 1269-77	3.9	5
561	Remission in early rheumatoid arthritis defined by 28 joint counts: limited consequences of residual disease activity in the forefeet on outcome. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 33-7	2.4	24
560	Usefulness of patients-reported outcomes in rheumatoid arthritis focus group. 2012 , 2012, 935187		26
559	Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1671-9	2.4	46
558	[Treat-to-target and remission: current strategies in rheumatoid arthritis]. 2012 , 137, 1761-5		

557	Current treatments of rheumatoid arthritis: from the 'NinJa' registry. 2012 , 8, 455-65		37
556	Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA. <i>Rheumatology</i> , 2012 , 51, 670-8	3.9	12
555	Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: are they equivalent?. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1942-9	2.4	50
554	Bedtime single-dose prednisolone in clinically stable rheumatoid arthritis patients. 2012 , 2012, 637204		2
553	A simplified version of Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with ankylosing spondylitis. 2012 , 31, 1599-603		14
552	Rheumatoid arthritis disease measurement: a new old idea. <i>Rheumatology</i> , 2012 , 51 Suppl 6, vi21-7	3.9	29
551	Initial management of rheumatoid arthritis. 2012 , 38, 311-25		15
550	Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. 2012 , 64, 1794-803		130
549	Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging?. 2012 , 64, 1846-54		24
548	Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. 2012 , 64, 3850-5		61
547	Tight disease control in early RA. 2012 , 38, 327-43		10
546	Should we use poor prognosis factors to start early treatment in patients with rheumatoid arthritis?. 2012 , 8, 163-7		0
545	Autofeedback from ultrasound images provides rapid improvement in palpation skills for identifying joint swelling in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2012 , 39, 1207-14	4.1	17
544	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1190-6	2.4	56
543	Évaluation des autoquestionnaires d'activité dans la polyarthrite rhumatoïde : étude transversale sur 200 patients avec le RAPID3 et le RADAI5 et évaluation de la poussée. 2012 , 79, 46-51		
542	Taking advances from bench to bedside during the last decade. 2012 , 26, 225-36		3
541	Should We Use Poor Prognosis Factors to Start Early Treatment in Patients With Rheumatoid Arthritis?. 2012 , 8, 163-167		
540	My treatment approach to rheumatoid arthritis. 2012 , 87, 659-73		73

539	Disease activity assessment and patient-reported outcomes in patients with early rheumatoid arthritis. 2012 , 38, 299-310	5
538	Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI. 2012 , 32, 3631-7	23
537	Sustained rheumatoid arthritis remission is uncommon in clinical practice. <i>Arthritis Research and Therapy</i> , 2012 , 14, R68	5:7 72
536	The relationship of metabolic syndrome with disease activity and the functional status in patients with rheumatoid arthritis. 2012 , 4, 279-85	16
535	NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab. 2012 , 6, 83-7	8
534	Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. 2012 , 64, 640-7	44 ^o
533	Metrologic properties of ultrasound versus clinical evaluation of synovitis in rheumatoid arthritis: results of a multicenter, randomized study. 2012 , 64, 1272-82	43
532	Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. 2012 , 64, 1316-22	37
531	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. 2012 , 64, 625-39	1199
530	Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. 2012 , 32, 1967-75	25
529	Evaluation of self-report questionnaires for assessing rheumatoid arthritis activity: a cross-sectional study of RAPID3 and RADA15 and flare detection in 200 patients. 2012 , 79, 57-62	24
528	Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. 2012 , 79, 149-55	80
527	Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients. 2012 , 31, 469-77	11
526	The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. 2013 , 32, 787-95	19
525	Hip score and disease activity correlation in patients with rheumatoid arthritis after total hip arthroplasty. 2013 , 37, 1245-50	5
524	Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort. 2013 , 17, 49-56	44
523	[Therapeutic update in rheumatoid arthritis]. 2013 , 34, 754-62	2
522	Outcome assessments in rheumatoid arthritis. 2013 , 15, 370	8

521	Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study. <i>Arthritis Research and Therapy</i> , 2013 , 15, R135	5.7	32
520	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. <i>Rheumatology</i> , 2013 , 52, 1202-7	3.9	65
519	Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1445-52	2.4	125
518	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. 2013 , 65, 28-38		186
517	Correlaci3n y concordancia de la autoclimetr3a en artritis reumatoide: revisi3n sistem3tica de la literatura y met3n3lisis. 2013 , 20, 30-57		3
516	Comparative validation of clinical disease activity index (CDAI) and simplified disease activity index (SDAI) in rheumatoid arthritis in India. 2013 , 8, 102-106		4
515	An3lisis hist3rico de la clinimetr3a y de la autoclimetr3a. Estado del arte. 2013 , 20, 1-8		
514	CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. 2013 , 5, 173ra23		449
513	Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study. 2013 , 33, 2373-9		12
512	Predictors and persistence of new-onset clinical remission in rheumatoid arthritis patients. 2013 , 43, 137-43		16
511	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 64-71	2.4	161
510	Development and validation of a new disease activity index as a numerical sum of four variables in patients with early arthritis. 2013 , 65, 518-25		10
509	Clinical disease activity assessments in rheumatoid arthritis. 2013 , 8, 347-360		15
508	Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. 2013 , 32, 1275-81		15
507	Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. 2013 , 3, e003554		39
506	Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1812-22	4.1	27
505	M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis. 2013 , 65, 3045-50		18
504	The correlation between cardiovascular risk and functional disability and disease activity in patients with rheumatoid arthritis. 2013 , 43, 919-927		0

503	Remission in rheumatoid arthritis: a comparison of the 2 newly proposed ACR/EULAR remission criteria with the rheumatoid arthritis disease activity index-5, a patient self-report disease activity index. <i>Journal of Rheumatology</i> , 2013 , 40, 394-400	4.1	8
502	Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1505-12	4.1	7
501	Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 241-4	2.4	31
500	Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 381-9	2.4	76
499	Patient self-assessment and physician's assessment of rheumatoid arthritis activity: which is more realistic in remission status? A comparison with ultrasonography. <i>Rheumatology</i> , 2013 , 52, 2243-50	3.9	23
498	Clinical and ultrasound-based composite disease activity indices in rheumatoid arthritis: results from a multicenter, randomized study. 2013 , 65, 879-87		21
497	Golimumab, a human anti-tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. 2013 , 65, 1732-42		29
496	Compression test (Gaenslen's squeeze test) positivity, joint tenderness, and disease activity in patients with rheumatoid arthritis. 2013 , 65, 653-7		11
495	Reexamination of the assessment criteria for rheumatoid arthritis disease activity based on comparison of the Disease Activity Score 28 with other simpler assessment methods. <i>Modern Rheumatology</i> , 2013 , 23, 260-268	3.3	6
494	A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study. <i>Modern Rheumatology</i> , 2013 , 23, 245-253	3.3	8
493	Selective reactivation of human herpesvirus 6 in patients with autoimmune connective tissue diseases. 2013 , 85, 1925-34		44
492	Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 875-80	2.4	55
491	Down titration and discontinuation strategies of tumor necrosis factor blocking agents for rheumatoid arthritis in patients with low disease activity. 2013 ,		
490	Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly. <i>Modern Rheumatology</i> , 2013 , 23, 994-1000	3.3	3
489	Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab. <i>Modern Rheumatology</i> , 2013 , 23, 1205-1210	3.3	10
488	C-reactive protein versus erythrocyte sedimentation rate in estimating the 28-joint disease activity score. <i>Journal of Rheumatology</i> , 2013 , 40, 1785-7	4.1	9
487	Critical Issues in Drug Development for SLE. 2013 , 648-652		1
486	Long-term Safety and Efficacy of Abatacept in Koreans with Rheumatoid Arthritis. 2013 , 20, 30		1

485	Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. 2014 , 2014, 528105		53
484	Regulation of cartilage and inflammatory biomarkers in rheumatoid arthritis patients treated with green tea therapy. 2014 , 8, 263-273		5
483	Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. 2014 , 66, 15-23		47
482	Evaluation of tocilizumab therapy in patients with rheumatoid arthritis based on FDG-PET/CT. 2014 , 15, 393		24
481	Etanercept in moderate rheumatoid arthritis: PRESERVE study results from central/eastern Europe, Latin America and Asia. 2014 , 9, 415-430		2
480	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. 2014 , 14, 350-5		23
479	Rheumatoid arthritis: recommendations for treat to target. 2014 , 23, 310-5		3
478	A nationwide cross-sectional overview of patients with rheumatoid arthritis followed in outpatient specialty clinics in Finland. 2014 , 43, 286-90		4
477	The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy. <i>Journal of Rheumatology</i> , 2014 , 41, 1607-13	4.1	18
476	Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with biologic therapies. <i>Journal of Rheumatology</i> , 2014 , 41, 1600-6	4.1	2
475	Ultrasound of synovitis in rheumatoid arthritis: advantages of the dorsal over the palmar approach to finger joints. <i>Journal of Rheumatology</i> , 2014 , 41, 422-8	4.1	16
474	Outcome Measures in Rheumatoid Arthritis. 2014 , 127-140		
473	Weighting with the Lansbury articular index improves the correlation of ultrasound score with serum matrix metalloproteinase-3 level in rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2014 , 24, 915-9	3.3	6
472	Clinically important changes in short form 36 health survey scales for use in rheumatoid arthritis clinical trials: the impact of low responsiveness. 2014 , 66, 1783-9		56
471	Clinical measurement of disease activity in rheumatoid arthritis: why, how and utility of patient self-assessment. 2014 , 9, 327-339		
470	Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2152-9	2.4	23
469	Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study. 2014 , 30, 2139-49		11
468	Understanding Evidence-Based Rheumatology. 2014 ,		

467	Tightening up? Impact of musculoskeletal ultrasound disease activity assessment on early rheumatoid arthritis patients treated using a treat to target strategy. 2014 , 66, 19-26		43
466	Present role of positron emission tomography in the diagnosis and monitoring of peripheral inflammatory arthritis: a systematic review. 2014 , 66, 120-30		17
465	The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. 2014 , 15, 452		19
464	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1755-60	2.4	10
463	Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis. 2014 , 3, e001267		44
462	Lack association of body mass index with disease activity composites of rheumatoid arthritis in Korean population: cross-sectional observation. 2014 , 33, 485-92		13
461	Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. 2014 , 58, 120-30		39
460	Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis. 2014 , 16, 417		10
459	Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. 2014 , 66, 794-802		43
458	Performance of Routine Assessment of Patient Index Data 3 (RAPID3) for assessment of rheumatoid arthritis in clinical practice: differential agreement of RAPID3 according to disease activity categories. 2014 , 34, 1311-8		12
457	Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 536-43	2.4	74
456	Contributions of ultrasound beyond clinical data in assessing inflammatory disease activity in rheumatoid arthritis: current insights and future prospects. <i>Rheumatology</i> , 2014 , 53, 2136-42	3.9	20
455	Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 86-94	2.4	197
454	Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. 2014 , 81, 287-97		100
453	Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde. 2014 , 81, 303-312		7
452	Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis. 2014 , 12, 129		10
451	Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. 2014 , 33, 623-9		10
450	Remission criteria and activity indices in psoriatic arthritis. 2014 , 33, 1323-30		33

449	Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort. 2014 , 33, 1061-6		19
448	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014 , 16, R56	5.7	84
447	Advantages of a combined rheumatoid arthritis magnetic resonance imaging score (RAMRIS) for hand and feet: does the RAMRIS of the hand alone underestimate disease activity and progression?. 2014 , 15, 104		9
446	Synovitis in patients with early inflammatory arthritis monitored with quantitative analysis of dynamic contrast-enhanced optical imaging and MR imaging. 2014 , 270, 176-85		41
445	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. 2014 , 383, 321-32		196
444	Revising DAS28 scores for remission in rheumatoid arthritis. 2014 , 33, 269-72		15
443	Increased plasma lactoferrin levels in leucocytapheresis therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2014 , 53, 1966-72	3.9	2
442	The learning curve of nurses for the assessment of swollen and tender joints in rheumatoid arthritis. 2014 , 81, 154-9		11
441	Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. 2014 , CD010455		38
440	Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial. 2015 , 67, 1627-36		11
439	Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion. 2015 , 67, 2855-60		7
438	Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naïve patients with Early Rheumatoid Arthritis (A-GREE). <i>Arthritis Research and Therapy</i> , 2015 , 17, 157	5.7	26
437	Utilizing the METEOR initiative to improve rheumatoid arthritis patient care. 2015 , 10, 425-431		
436	Reliability and validity of CDAI and SDAI indices in comparison to DAS-28 index in Moroccan patients with rheumatoid arthritis. 2015 , 16, 268		9
435	Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015 , 17, 229	5.7	51
434	The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study. 2015 , 67, 2591-600		63
433	Lipid extract from hard-shelled mussel (<i>Mytilus coruscus</i>) improves clinical conditions of patients with rheumatoid arthritis: a randomized controlled trial. 2015 , 7, 625-45		16
432	Patient Acceptable Symptom State in Self-Report Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care. 2015 , 2015, 930756		32

431	Serum Markers in Rheumatoid Arthritis: A Longitudinal Study of Patients Undergoing Infliximab Treatment. 2015 , 2015, 276815		7
430	Atlas of Rheumatoid Arthritis. 2015 ,		2
429	Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 252	5.7	42
428	Review of rheumatoid arthritis disease outcome measures: Recommendations and its relevance in private practice. 2015 , 10, 133-139		
427	Validation of RAPID3 using a Japanese version of Multidimensional Health Assessment Questionnaire with Japanese rheumatoid arthritis patients: characteristics of RAPID3 compared to DAS28 and CDAI. <i>Modern Rheumatology</i> , 2015 , 25, 264-9	3.3	6
426	Dopamine receptor DR2 expression in B cells is negatively correlated with disease activity in rheumatoid arthritis patients. 2015 , 220, 323-30		14
425	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 532-7	2.4	9
424	Ras guanine nucleotide-releasing protein 4 is aberrantly expressed in the fibroblast-like synoviocytes of patients with rheumatoid arthritis and controls their proliferation. 2015 , 67, 396-407		14
423	Associations of toll-like receptor (TLR)-4 single nucleotide polymorphisms and rheumatoid arthritis disease progression: an observational cohort study. 2015 , 24, 346-352		23
422	Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. <i>Modern Rheumatology</i> , 2015 , 25, 43-9	3.3	8
421	Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2015 , 25, 817-24	3.3	62
420	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. <i>Modern Rheumatology</i> , 2015 , 25, 344-9	3.3	14
419	Place de l'rhographie dans la polyarthrite rhumatoïde en rmission. 2015 , 82, 225-232		1
418	Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy. 2015 , 67, 63-73		39
417	Validity and responsiveness of a self-administered foot evaluation questionnaire in rheumatoid arthritis. <i>Modern Rheumatology</i> , 2015 , 25, 358-61	3.3	7
416	Remission in rheumatoid arthritis: is it all the same?. 2015 , 8, 575-86		9
415	Correlation of rheumatoid arthritis activity indexes (Disease Activity Score 28 measured with ESR and CRP, Simplified Disease Activity Index and Clinical Disease Activity Index) and agreement of disease activity states with various cut-off points in a Northeastern Brazilian population. 2015 , 55, 477-484		0
414	Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA). 2015 , 16, 73		2

413	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 14	5.7	37
412	Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. <i>Rheumatology</i> , 2015 , 54, 2188-97	3.9	8
411	Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1676-83	2.4	17
410	Correlation of rheumatoid arthritis activity indexes (Disease Activity Score 28 measured with ESR and CRP, Simplified Disease Activity Index and Clinical Disease Activity Index) and agreement of disease activity states with various cut-off points in a Northeastern Brazilian population. 2015 , 55, 477-84		12
409	Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index. <i>Rheumatology</i> , 2015 , 54, 1033-8	3.9	8
408	Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 381-84	2.4	101
407	Treatment of rheumatoid arthritis with methotrexate alone and in combination with other conventional DMARDs using the T2T strategy. A cohort study. 2015 , 34, 215-20		17
406	Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1691-6	2.4	66
405	DAS28, CDAI and SDAI cut-offs do not translate the same information: results from the Rheumatic Diseases Portuguese Register Reuma.pt. <i>Rheumatology</i> , 2015 , 54, 286-91	3.9	16
404	Efficacy and safety of mavrimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study. <i>Modern Rheumatology</i> , 2015 , 25, 21-30	3.3	31
403	Are We Able to Suppress Disease Activity Adequately in Patients With Established Rheumatoid Arthritis? An Observational and Cross-Sectional Study. 2016 , 31, 127-132		
402	Obesity Associated With Active, but Preserved Joints in Rheumatoid Arthritis: Results From our National Registry. 2016 , 31, 272-280		1
401	Silibinin Improves the Effects of Methotrexate in Patients with Active Rheumatoid Arthritis: Pilot Clinical Study. 2016 , 31, 263-9		10
400	The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis. 2016 , 31, 202-7		39
399	Alteration of matrix metalloproteinase-3 O-glycan structure as a biomarker for disease activity of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 112	5.7	11
398	Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. <i>Arthritis Research and Therapy</i> , 2016 , 18, 160	5.7	28
397	Does a Simplified 6-Joint Ultrasound Index Correlate Well Enough With the 28-Joint Disease Activity Score to Be Used in Clinical Practice?. <i>Journal of Clinical Rheumatology</i> , 2016 , 22, 179-83	1.1	6
396	Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab. 2016 , 68, 2083-9		35

395	Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. 2016 , 68, 899-906		30
394	Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission. 2016 , 68, 1616-1623		24
393	A model-based evaluation of single metrics for discriminating changes in rheumatoid arthritis disease activity. 2016 , 81, 1046-57		1
392	Assessment Tools in Juvenile Idiopathic Arthritis. 2016 , 11, 107-127		
391	Increased healthcare resource utilization in higher disease activity levels in initiators of TNF inhibitors among US rheumatoid arthritis patients. 2016 , 32, 1959-1967		5
390	Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 2087-2094	2.4	47
389	Urinary interleukin-6 as a predictor of radiographic progression in rheumatoid arthritis: A 3-year evaluation. 2016 , 6, 35242		5
388	Patient-Reported Outcomes in Rheumatoid Arthritis. 2016 , 42, 219-37		20
387	Baricitinib in Patients with Refractory Rheumatoid Arthritis. 2016 , 374, 1243-52		365
386	Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. <i>Rheumatology</i> , 2016 , 55, 1601-9	3.9	18
385	A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). 2016 , 17, 61		8
384	The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles. <i>Journal of Rheumatology</i> , 2016 , 43, 1300-5	4.1	31
383	Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions. <i>Journal of Rheumatology</i> , 2016 , 43, 1285-91	4.1	20
382	Rheumatoid arthritis. 2016 , 388, 2023-2038		1794
381	A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. 2016 , 68, 2867-2877		122
380	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. 2016 , 44, 113-118		11
379	Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial. 2016 , 68, 744-52		28
378	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 , 68, 1-25		717

377	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 2016 , 68, 1-26		1274
376	Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2016 , 43, 1643-9	4.1	8
375	Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. 2016 , 68, 2857-2866		139
374	SASDAS (simplified version of ankylosing spondylitis disease activity score)-ESR performance and development of SASDAS-CRP and their agreement with ASDAS-ESR and ASDAS-CRP in patients with ankylosing spondylitis. 2016 , 35, 2865-2866		5
373	Validation of disease activity indices using the 28 joint counts in systemic sclerosis. <i>Rheumatology</i> , 2016 , 55, 1849-58	3.9	10
372	Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor. 2016 , 44, 90-94		8
371	Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria. <i>Rheumatology</i> , 2016 , 55, 1954-1958	3.9	6
370	Clinical joint inactivity predicts structural stability in patients with established rheumatoid arthritis. <i>RMD Open</i> , 2016 , 2, e000241	5.9	6
369	Ultrasound-detected joint inflammation and B cell count: related variables for rituximab-treated RA patients?. 2016 , 36, 793-7		
368	Use of magnetic resonance imaging in detecting subclinical synovitis in rheumatoid arthritis and correlation of imaging findings with interleukin-18 levels. 2016 , 19, 790-8		6
367	HLA-DRB1 alleles in Egyptian rheumatoid arthritis patients: Relations to anti-cyclic citrullinated peptide antibodies, disease activity and severity. 2016 , 38, 269-275		3
366	Rheumatoid Arthritis (RA). 2016 , 11, 1-10		
365	Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. 2016 , 111, 264-271		21
364	Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. 2016 , 68, 1914-21		56
363	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 16-22	2.4	156
362	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 3-15	2.4	814
361	Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. <i>Rheumatology</i> , 2016 , 55, 640-8	3.9	22
360	RENACER study: Assessment of 12-month efficacy and safety of 168 certolizumab PEGol rheumatoid arthritis-treated patients from a Spanish multicenter national database. <i>Modern Rheumatology</i> , 2016 , 26, 336-341	3.3	7

359	The synovial grade corresponding to clinically involved joints and a feasible ultrasound-adjusted simple disease activity index for monitoring rheumatoid arthritis. <i>Modern Rheumatology</i> , 2016 , 26, 844-849		1
358	Identification of novel urinary biomarkers for assessing disease activity and prognosis of rheumatoid arthritis. 2016 , 48, e211		20
357	[Cardiovascular disease and systemic inflammatory diseases]. 2016 , 28, 94-101		1
356	Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis. 2016 , 78, 87-93		29
355	The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice. <i>Modern Rheumatology</i> , 2016 , 26, 499-506	3.3	12
354	Biologics for the Treatment of Rheumatoid Arthritis. 2016 ,		1
353	Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 811-8	2.4	202
352	Comparison of golimumab 100-mg monotherapy to golimumab 50 mg plus methotrexate in patients with rheumatoid arthritis: Results from a multicenter, cohort study. <i>Modern Rheumatology</i> , 2016 , 26, 24-8	3.3	4
351	High-resolution CT and pulmonary function tests in rheumatoid arthritis patients with subclinical interstitial lung disease in Kuwait. 2016 , 38, 77-83		4
350	Premature senescence of T-cell subsets in axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 748-54	2.4	22
349	Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment. 2017 , 35, 52-57		21
348	Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users. 2017 , 37, 897-904		16
347	Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al. 2017 , 69, 863-865		8
346	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 960-974		1649
345	Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. 2017 , 376, 652-662		427
344	Low Prevalence of Nodules in Rheumatoid Arthritis Patients in Kuwait: A Description and a Comparison of Patients from the Kuwait Registry for Rheumatic Diseases. 2017 , 26, 152-156		4
343	Reply. 2017 , 69, 867-868		2
342	Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study. 2017 , 72, 424-428		1

341	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. 2017 , 69, 728-734		29
340	Comparison between different disease activity scores in rheumatoid arthritis: an Egyptian multicenter study. 2017 , 36, 2217-2224		3
339	HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 113	5.7	23
338	Low disease activity (DAS28.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1693-1699	2.4	54
337	A reduced 12-joint ultrasound examination predicts lack of X-ray progression better than clinical remission criteria in patients with rheumatoid arthritis. 2017 , 37, 1347-1356		6
336	Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2017 , 44, 553-557	4.1	6
335	Predictive factors associated with the progression of large-joint destruction in patients with rheumatoid arthritis after biologic therapy: A post-hoc analysis using FDG-PET/CT and the ARASHI (assessment of rheumatoid arthritis by scoring of large-joint destruction and healing in radiographic imaging) scoring method. <i>Modern Rheumatology</i> , 2017 , 27, 820-827	3.3	10
334	Effects of Baricitinib on Lipid, Apolipoprotein, and Lipoprotein Particle Profiles in a Phase IIb Study of Patients With Active Rheumatoid Arthritis. 2017 , 69, 943-952		31
333	Achieving simplified disease activity index remission in patients with active rheumatoid arthritis is associated with subsequent good functional and structural outcomes in a real-world clinical setting under a treat-to-target strategy. <i>Modern Rheumatology</i> , 2017 , 27, 811-819	3.3	6
332	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 88-95	2.4	222
331	Évaluation de l'activité de la polyarthrite rhumatoïde. 2017 , 84, 343-346		
330	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017 , 3, e000445	5.9	4
329	Cost-Effectiveness Analysis of Etanercept in Combination with Methotrexate for Rheumatoid Arthritis - Markov Model Based on Data from Serbia. 2017 , 18, 343-347		1
328	Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 2054-2060	2.4	16
327	Patterns of circulatory and peripheral blood mononuclear cytokines in rheumatoid arthritis. 2017 , 37, 1727-1734		15
326	A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. 2017 , 69, 1937-1948		21
325	Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. 2017 , 69, 518-528		13
324	Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: Integrating systematic literature research and expert opinion of the Thai Rheumatism Association. 2017 , 20, 1142-1165		5

323	Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study. 2017 , 46, 87-94		19
322	Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort. 2017 , 69, 737-741		2
321	Concordance of Patient-Reported Joint Symptoms, Physician-Examined Arthritic Signs, and Ultrasound-Detected Synovitis in Rheumatoid Arthritis. 2017 , 69, 801-806		15
320	Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab. 2017 , 69, 609-615		10
319	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor. 2017 , 69, 783-793		25
318	Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. <i>Modern Rheumatology</i> , 2017 , 27, 237-245	3-3	46
317	Neutrophil-to-lymphocyte ratio is a reliable marker of treatment response in rheumatoid arthritis patients during tocilizumab therapy. <i>Modern Rheumatology</i> , 2017 , 27, 405-410	3-3	15
316	Effect of total knee arthroplasty on other joints in patients with rheumatoid arthritis evaluated by 18-FDG-PET. 2017 , 20, 702-707		5
315	Effectiveness and safety of tocilizumab in achieving clinical and functional remission, and sustaining efficacy in biologics-naïve patients with rheumatoid arthritis: The FIRST Bio study. <i>Modern Rheumatology</i> , 2017 , 27, 217-226	3-3	23
314	Do Short and Sustained Periods of American College of Rheumatology/European League Against Rheumatism Remission Predict Functional and Radiographic Outcome in Early Rheumatoid Arthritis Patients With Low Overall Damage Progression?. 2017 , 69, 989-996		7
313	The adjuvant use of calcium fructoborate and borax with etanercept in patients with rheumatoid arthritis: Pilot study. 2017 , 6, 58-64		5
312	Novel Senescent Regulatory T-Cell Subset with Impaired Suppressive Function in Rheumatoid Arthritis. 2017 , 8, 300		32
311	Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. <i>Arthritis Research and Therapy</i> , 2017 , 19, 155	5-7	37
310	Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 221	5-7	22
309	Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 218	5-7	29
308	Incretins in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 229	5-7	8
307	A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 231	5-7	6
306	Drug-free remission: the goal of the future in management of patients with rheumatoid arthritis. <i>Reumatologia</i> , 2017 , 55, 284-289	1-7	3

305	Treatment of Rheumatoid Arthritis. 2017 , 1187-1212.e5		
304	[Early undifferentiated arthritis]. 2018 , 47, 261-272		
303	Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study. 2018 , 37, 1449-1455		2
302	Physician global assessments for disease activity in rheumatoid arthritis are all over the map!. <i>RMD Open</i> , 2018 , 4, e000578	5.9	4
301	Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. 2018 , 5, 43-55		2
300	The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. 2018 , 15, 291-301		13
299	Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis. 2018 , 4, FSO289		2
298	Changes in thiol/disulfide homeostasis in juvenile idiopathic arthritis. 2018 , 60, 593-596		9
297	The Dorsal 4-finger Technique: A Novel Method to Examine Metacarpophalangeal Joints in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 329-334	4.1	1
296	Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics. <i>RMD Open</i> , 2018 , 4, e000581	5.9	10
295	Rheumatoid arthritis. 2018 , 4, 18001		750
294	Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. 2018 , 70, 832-840		74
293	[Rheumatoid arthritis and polycythemia vera JAK2 negative association: Polycythemia may be worsening under methotrexate?]. 2018 , 73, 351-353		0
292	Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis. 2018 , 18, 167-172		17
291	Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial. 2018 , 85, 59-64		8
290	Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. 2018 , 21, 1933-1939		19
289	Relevance of P-glycoprotein on CXCR4 B cells to organ manifestation in highly active rheumatoid arthritis. <i>Modern Rheumatology</i> , 2018 , 28, 276-286	3.3	10
288	Safety and effectiveness of tacrolimus add-on therapy for rheumatoid arthritis patients without an adequate response to biological disease-modifying anti-rheumatic drugs (DMARDs): Post-marketing surveillance in Japan. <i>Modern Rheumatology</i> , 2018 , 28, 48-57	3.3	9

287	The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis. 2018 , 47, 619-629		9
286	Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. 2018 , 70, 40-48		75
285	A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. 2018 , 70, 49-59		58
284	Concordance and correlation of activity indices in patients with rheumatoid arthritis in northwestern Colombia: A cross-sectional study. 2018 , 21, 1946-1954		1
283	Assessing joint destruction in the knees of patients with rheumatoid arthritis by using a semi-automated software for magnetic resonance imaging: therapeutic effect of methotrexate plus etanercept compared with methotrexate monotherapy. <i>Modern Rheumatology</i> , 2018 , 28, 235-241	3.3	
282	Pain Catastrophizing, Subjective Outcomes, and Inflammatory Assessments Including Ultrasound: Results From a Longitudinal Study of Rheumatoid Arthritis Patients. 2018 , 70, 703-712		26
281	Joint index vector: a novel assessment measure for stratified medicine in patients with rheumatoid arthritis. 2018 , 5,		0
280	Causal Relationships Between Modifiable Risk Factors of Cognitive Impairment, Cognitive Function, Self-Management, and Quality of Life in Patients With Rheumatic Diseases. 2018 , 37, 305-315		1
279	Performance of routine assessment of patient index data 3 (RAPID3) in monitoring disease activity of Chinese rheumatoid arthritis patients. 2018 , 21, 1940-1945		
278	Efficacy of infliximab as a switched biologic in rheumatoid arthritis patients in daily clinical practice. 2018 , 41, 181-186		4
277	Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 275	5.7	14
276	Real World Experience of Disease Activity in Patients With Rheumatoid Arthritis and Response to Treatment With Various Biologic DMARDs. 2018 , 9, 1303		4
275	Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors. 2018 , 7,		37
274	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018 , 4, e000773 ⁵⁹		5
273	Rheumatoid Arthritis. 2018 ,		5
272	Assessment of Disease Activity, Structural Damage, and Function in Rheumatoid Arthritis. 2018 , 1868, 243-250		0
271	Design an Intervention Study. 2018 , 1868, 235-241		1
270	[What is certain in the treatment of rheumatoid arthritis?]. 2018 , 59, 1249-1254		1

269	Disease activity assessment in patients with psoriatic arthritis. 2018 , 32, 401-414		8
268	Intensive therapy and remissions in rheumatoid arthritis: a systematic review. 2018 , 19, 389		15
267	Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis - results from the CHIKARA study. 2018 , 21, 1962-1969		22
266	Features of patients with rheumatoid arthritis whose debut joint is a foot or ankle joint: A 5,479-case study from the IORRA cohort. 2018 , 13, e0202427		18
265	Azilsartan as "Add-On" Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis. 2018 , 2018, 7164291		6
264	Common Evaluations of Disease Activity in Rheumatoid Arthritis Reach Discordant Classifications across Different Populations. 2018 , 5, 40		14
263	Rheumatoid Arthritis: A Novel Approach in Diagnosis and Treatment. 2018 ,		
262	Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. 2018 , 9, 2755		63
261	Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study. 2018 , 48, 374-383		9
260	Interpretation of DAS28 and its components in the assessment of inflammatory and non-inflammatory aspects of rheumatoid arthritis. 2018 , 2, 8		13
259	Azilsartan improves the effects of etanercept in patients with active rheumatoid arthritis: a pilot study. 2018 , 14, 1379-1385		4
258	The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study. <i>Annals of the Rheumatic Diseases</i> , 2019 , 77, 1000-1006	2.4	34
257	Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study. 2019 , 48, 808-814		15
256	Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF- κ B and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients. <i>Modern Rheumatology</i> , 2019 , 29, 418-429	3.3	12
255	Performance of serum adenosine deaminase in measuring disease activity in rheumatoid arthritis patients. 2019 , 41, 81-85		6
254	Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation. 2019 , 39, 2137-2145		1
253	Association between interleukin-21 gene rs6822844 polymorphism and rheumatoid arthritis susceptibility. 2019 , 39,		3
252	Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. 2019 , 322, 315-325		117

251	Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis. 2019 , 132, 1009-1014		9
250	Predictors and the optimal duration of sustained remission in rheumatoid arthritis. 2019 , 38, 3033-3039		3
249	A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis - results of clinical relevance. 2019 , 11, 207-217		7
248	Efficacy and safety of original and biosimilar etanercept (SB4) in active rheumatoid arthritis - A comparison in a real-world national cohort. 2019 , 62, 27-32		6
247	Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study. 2019 , 20, 420		7
246	The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. <i>Rheumatology</i> , 2019 , 58, 2091-2098	3.9	10
245	Association between severity of periodontitis and clinical activity in rheumatoid arthritis patients: a case-control study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 27	5.7	50
244	Effect of IL-6 Receptor Blockade on Proprotein Convertase Subtilisin/Kexin Type-9 and Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients. 2019 , 51, 200-209		18
243	Rheumatoid arthritis: 'melting pot' of T helper subsets. 2019 , 38, 212-231		10
242	Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1179-1185	2.4	14
241	A Study of the Vascular Endothelial Function in Patients with Type 2 Diabetes Mellitus and Rheumatoid Arthritis. 2019 , 58, 1383-1390		10
240	Rheumatoid Arthritis. 2019 , 501-526		2
239	Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. 2019 , 71, 1616-1625		8
238	Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components. 2019 , 85, 1710-1718		5
237	Effect of periodontal therapy on disease activity in patients of rheumatoid arthritis with chronic periodontitis. 2019 , 9, 128-132		17
236	A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. 2019 , 37, 829-843		15
235	Mediastinal and axillar lymphadenopathy in patients with rheumatoid arthritis: prevalence and clinical significance. 2019 , 55, 140-143		3
234	Risk profiling for a refractory course of rheumatoid arthritis. 2019 , 49, 211-217		32

233	When the first visit to the rheumatologist is established rheumatoid arthritis. 2019 , 33, 101479		3
232	Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. 2019 , 5, CD010455		12
231	Genetic polymorphisms of ACE I/D, IL-1 β > A and IL-4 VNTR among Egyptian subjects with rheumatoid arthritis. 2019 , 1-10		6
230	Comparisons of the Incidence and Critical Risk Factors of Metabolic Syndrome in Patients With a Rheumatic Disease or Gout. 2019 , 38, 201-208		1
229	Safety of Intra-articular Methotrexate Injection With and Without Electroporation for Inflammatory Small Joints in Patients With Rheumatoid Arthritis. 2019 , 12, 1179544119886303		3
228	Safety of combination therapy with two bDMARDs in patients with rheumatoid arthritis: A systematic review and meta-analysis. 2019 , 49, 35-42		13
227	Measuring disease activity and response to treatment in rheumatoid arthritis. 2019 , 15, 135-145		2
226	Rheumatoid Arthritis. 2019 , 170, ITC1-ITC16		193
225	Identification of symptom clusters and their synergistic effects on quality of life in rheumatoid arthritis patients. 2019 , 25, e12713		3
224	Impact of subclinical synovitis in ankles and feet detected by ultrasonography in patients with rheumatoid arthritis. 2019 , 22, 62-67		4
223	Contribution of the bone and cartilage/soft tissue components of the joint damage to the level of disability in rheumatoid arthritis patients: a longitudinal study. 2019 , 38, 691-700		6
222	Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores. 2019 , 38, 437-445		7
221	Validity and interpretability of the QuickDASH in the assessment of hand disability in rheumatoid arthritis. 2019 , 39, 923-932		6
220	Relationship Between Insulin Sensitivity and β Cell Secretion in Nondiabetic Subjects with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 229-236	4.1	6
219	Prevalence of sustained remission in rheumatoid arthritis: impact of criteria sets and disease duration, a Nationwide Study in Sweden. <i>Rheumatology</i> , 2019 , 58, 227-236	3.9	32
218	Tender Joint Count and Inflammatory Activity in Patients With Established Rheumatoid Arthritis: Results From a Longitudinal Study. 2020 , 72, 27-35		15
217	Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs. 2020 , 72, 942-949		0
216	Flares in rheumatoid arthritis: do patient-reported swollen and tender joints match clinical and ultrasonography findings?. <i>Rheumatology</i> , 2020 , 59, 129-136	3.9	9

215	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. 2020 , 50, 276-284		12
214	Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. 2020 , 50, 245-251		8
213	Validity and responsiveness of the Work Functioning Impairment Scale (WFun) in rheumatoid arthritis patients: A multicenter prospective study. <i>Modern Rheumatology</i> , 2020 , 30, 821-827	3.3	5
212	Ultrasonography supplements clinical exam to improve early rheumatoid arthritis disease activity monitoring in metatarsophalangeal joints. 2020 , 39, 1483-1491		3
211	Disease activity measures at baseline predict structural damage progression: data from the randomized, controlled AMPLE and AVERT trials. <i>Rheumatology</i> , 2020 , 59, 2090-2098	3.9	6
210	Rheumatoid Arthritis Patient's Journey: Delay in Diagnosis and Treatment. <i>Journal of Clinical Rheumatology</i> , 2020 , 26, S148-S152	1.1	5
209	Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry. 2020 , 2, 595-604		3
208	Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study. 2020 , 11, 1382		5
207	Reply. 2020 , 72, 1407-1408		
206	Measurement of overall perceived health using different scales in patients with rheumatoid arthritis: a proposal of a combined scale. 2020 , 27, 262-268		
205	Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatoid arthritis: A retrospective cohort study. 2020 , 99, e20966		1
204	Medici3 de la percepci3 global de salud mediante diferentes escalas en pacientes con artritis reumatoide: propuesta de una escala combinada. 2020 , 27, 262-268		
203	Simplified disease activity index and clinical disease activity index before and during pregnancy correlate with those at postpartum in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2021 , 31, 809-816	3.3	1
202	Association of age with the non-achievement of clinical and functional remission in rheumatoid arthritis. 2020 , 10, 15277		1
201	Assessment of Serum Lipid Profiles and High-sensitivity C-reactive Protein Among Patients Suffering from Rheumatoid Arthritis at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Study. 2020 , 12, 223-232		3
200	The Performance of Vascular Age in the Assessment of Cardiovascular Risk of Patients with Rheumatoid Arthritis. 2020 , 9,		0
199	A Proposal to Standardize Low Disease Activity Criteria in Rheumatoid Arthritis Based on the Outcome Measures in Rheumatology Minimal Disease Activity Definition. 2020 , 2, 301-306		1
198	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. 2020 , 80, 849-857		10

197	Altered Lymphatic Vessel Anatomy and Markedly Diminished Lymph Clearance in Affected Hands of Patients With Active Rheumatoid Arthritis. 2020 , 72, 1447-1455		7
196	A useful tool to assess quality of LIFE in rheumatoid arthritis patients that does not require a license: QOL-RA II. 2020 , 39, 3309-3315		
195	The Patient Experienced Symptom State (PESS): a patient-reported global outcome measure that may better reflect disease remission status. <i>Rheumatology</i> , 2020 , 59, 3458-3467	3.9	1
194	Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation. 2020 , 50, 749-758		0
193	[Management of early rheumatoid arthritis : Interdisciplinary guideline]. 2020 , 79, 1-38		11
192	Insights into the treatment of rheumatoid arthritis: A paradigm in medicine. 2020 , 110, 102425		9
191	The prevalence of insomnia and restless legs syndrome among Japanese outpatients with rheumatic disease: A cross-sectional study. 2020 , 15, e0230273		2
190	Future use of musculoskeletal ultrasonography and magnetic resonance imaging in rheumatoid arthritis. 2020 , 32, 264-272		5
189	Development of a multivariable improvement measure for gout. <i>Arthritis Research and Therapy</i> , 2020 , 22, 164	5.7	2
188	Association between periodontitis and anti-citrullinated protein antibodies in rheumatoid arthritis patients: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 27	5.7	8
187	Influence of Ambient Air Pollution on Rheumatoid Arthritis Disease Activity Score Index. 2020 , 17,		15
186	Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry. 2020 , 18, 5		1
185	Translation and cross-cultural adaptation into Italian of the self-administered FLARE-RA questionnaire for rheumatoid arthritis. 2020 , 72, 21-30		1
184	Classifying Remission in Rheumatoid Arthritis Treat-to-Target Studies: Comment on the Article by Norvang et al. 2020 , 72, 1406-1407		
183	Validation of the HAQ-UP-A (Health Assessment Questionnaire-Upper Limbs-Argentine Version) in patients with rheumatoid arthritis. 2021 , 17, 20-24		1
182	Higher Prevalence and Degree of Insulin Resistance in Patients With Rheumatoid Arthritis Than in Patients With Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021 , 48, 339-347	4.1	2
181	Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. 2021 , 73, 649-657		2
180	Use of multidimensional composite scores in rheumatology: parsimony versus subtlety. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	1

179	Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis. 2021 , 40, 1739-1749		1
178	MRI wrist in early rheumatoid arthritis: reduction in inflammation assessed quantitatively during treatment period correlates best with clinical improvement. 2021 , 50, 1337-1345		2
177	What could a new disease activity score for polymyalgia rheumatica do better?. 2021 , 17, 185		2
176	Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2). <i>Modern Rheumatology</i> , 2021 , 1-16	3-3	2
175	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. 2021 , 73, 759-768		12
174	Why remission is not enough: underlying disease mechanisms in RA that prevent cure. 2021 , 17, 135-144		18
173	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021 , 60, 1137-1147	3-9	7
172	Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. 2021 , 13, 1759720X211022533		1
171	Special considerations on interventions. 2021 , 361-386		
170	Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis. 2021 , 73, 401-413		4
169	Switching first-line targeted therapy after not reaching low disease activity within 6 months is superior to conservative approach: a propensity score-matched analysis from the ATTRA registry. <i>Arthritis Research and Therapy</i> , 2021 , 23, 11	5-7	4
168	Morpho-structural characteristics of feet in patients with rheumatoid arthritis: A cross sectional study. 2021 , 18, 2269-2275		0
167	Adherence to Treatment with Tofacitinib in Patients with Rheumatoid Arthritis in Daily Clinical Practice. 2021 , 18, 164-164		2
166	Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis. 2021 , 40, 2665-2672		
165	Time in remission as an alternative outcome measure for rheumatoid arthritis: a 10-year prospective study of 2,618 new users of anti-TNF. <i>Rheumatology</i> , 2021 ,	3-9	
164	Validation of the HAQ-UP-A (Health Assessment Questionnaire-Upper Limbs-Argentine Version) in Patients With Rheumatoid Arthritis. 2021 , 17, 20-24		
163	Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?. 2021 , 13, 1759720X21993252		5
162	Modeling and Simulation to Support Phase Ib/IIa Dose Selection for WBP216, A Long Half-Life Fully Human Monoclonal Antibody Against Interleukin-6. 2021 , 12, 617265		0

161	Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity. <i>Modern Rheumatology</i> , 2021 , 31, 1094-1099	3.3	0
160	A Review on Rheumatoid Arthritis Interventions and Current Developments. 2021 , 22, 463-483		1
159	Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission. 2021 , 11, 6865		4
158	Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
157	Disease Activity Indices in Rheumatoid Arthritis: Comparative Performance to Detect Changes in Function, IL-6 Levels, and Radiographic Progression. 2021 , 8, 669688		1
156	Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial. 2021 , 325, 1755-1764		7
155	Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study. 2021 , 8, 987-1001		1
154	Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk. <i>Arthritis Research and Therapy</i> , 2021 , 23, 162	5.7	3
153	Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. 2021 , 51, 1360-1360		1
152	The Importance of Outcome Measures in the Management of Inflammatory Rheumatic Diseases. 2021 , 13, 191-200		
151	Adherence to treatment with tofacitinib in patients with rheumatoid arthritis in daily clinical practice. 2021 ,		
150	Bone erosions and osteophytes in premenopausal women with long-standing rheumatoid arthritis: association with systemic bone involvement by HR-Pqct. 2021 ,		0
149	Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients Receiving Combination Therapy: Comment on the Article by Curtis et al. 2021 , 73, 1771		1
148	Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 228	5.7	2
147	Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region. 2021 , 15, 100240		2
146	The feasibility of an exercise intervention to improve sleep (time, quality and disturbance) in people with rheumatoid arthritis: a pilot RCT. 2021 , 41, 297-310		1
145	Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis. 2021 , 50, 262-270		4
144	Development and validation of handy rheumatoid activity score with 38 joints (HRAS38) in rheumatoid arthritis patients receiving infliximab. <i>Modern Rheumatology</i> , 2006 , 16, 381-8	3.3	5

143	Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. <i>Modern Rheumatology</i> , 2007 , 17, 403-8	3.3	14
142	Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of the SATORI study. <i>Modern Rheumatology</i> , 2010 , 20, 539-47	3.3	19
141	Comparison of composite disease activity indices for rheumatoid arthritis. <i>Modern Rheumatology</i> , 2011 , 21, 134-43	3.3	5
140	A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study. <i>Modern Rheumatology</i> , 2013 , 23, 245-53	3.3	4
139	How to Define Boolean Low Disease Activity in Rheumatoid Arthritis: Experience from a Large Real-world Cohort. 2021 , 8, 289-301		3
138	Treatment of Rheumatoid Arthritis. 2009 , 1119-1143		4
137	Treatment of Rheumatoid Arthritis. 2013 , 1137-1160.e4		2
136	Evaluation and monitoring of established rheumatoid arthritis. 2019 , 33, 101480		1
135	Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. <i>Rheumatology</i> , 2016 , 55, 1826-36	3.9	23
134	Depression Is a Major Determinant of Functional Capacity in Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021 , 27, S180-S185	1.1	3
133	Three groups in the 28 joints for rheumatoid arthritis synovitis--analysis using more than 17,000 assessments in the KURAMA database. 2013 , 8, e59341		40
132	Inverse association between air pressure and rheumatoid arthritis synovitis. 2014 , 9, e85376		17
131	Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-Inhibitors in Rheumatoid Arthritis. 2016 , 11, e0163087		29
130	Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission. 2016 , 11, e0165498		8
129	Severity and Diurnal Improvement of Morning Stiffness Independently Associate with Tenosynovitis in Patients with Rheumatoid Arthritis. 2016 , 11, e0166616		8
128	Polymorphisms in STAT4, PTPN2, PSORS1C1 and TRAF3IP2 Genes Are Associated with the Response to TNF Inhibitors in Patients with Rheumatoid Arthritis. 2017 , 12, e0169956		18
127	Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. 2017 , 12, e0183420		19
126	Long noncoding RNA profiling revealed differentially expressed lncRNAs associated with disease activity in PBMCs from patients with rheumatoid arthritis. 2017 , 12, e0186795		37

125	The Effect of Neuropathic Pain Symptoms on Remission in Patients with Early Rheumatoid Arthritis. 2019 , 15, 154-161	13
124	Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it. 2019 , 15, 329-335	4
123	A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial. 2018 , 7, e84	11
122	[Biologic therapy of rheumatoid arthritis]. 2009 , 137, 205-10	3
121	Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. 2018 , 22, 1-280	7
120	Resting energy expenditure is not associated with disease activity in women with rheumatoid arthritis: cross-sectional study. 2014 , 29, 516-24	2
119	Conversion among the 28-joint count activity indices for rheumatoid arthritis. 2020 , 7, 105-111	3
118	Introductory Chapter: Rheumatoid Arthritis - Overview of Current Facts and Strategies.	1
117	Is painless synovitis different from painful synovitis? A controlled, ultrasound, radiographic, clinical trial. 2014 , 69, 93-100	6
116	A novel multi-biomarker combination predicting relapse from long-term remission after discontinuation of biological drugs in rheumatoid arthritis. 2021 , 11, 20771	1
115	Baseline predictors of different types of treatment success in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4 0
114	Outcome Measurement in Rheumatoid Arthritis: Disease Activity. 2009 , 225-230	1
113	Rheumatoid Arthritis. 2009 , 1-13	
112	Evaluation and outcomes of patients with rheumatoid arthritis. 2011 , 941-954.e1	1
111	Rheumatoid Arthritis: Diagnose Early and Treat to Target. 2012 , 123-136	
110	Disease Outcomes in Rheumatoid Arthritis. 2012 , 27-48	
109	Auswahl von Scores in der Rheumatologie. 2012 , 873-879	
108	Evaluation and outcomes of patients with rheumatoid arthritis. 2015 , 790-801	1

- 107 Metabolic Syndrome in Systemic Lupus Erythematosus. **2015**, 202-217
- 106 General Treatment Aspects. **2016**, 9-27
- 105 Planning of a Clinical Data Registry for Basic Anti-Inflammatory Drugs for the Treatment of Rheumatoid Arthritis. **2018**, 8, 238-245 1
- 104 THE ASSESSMENT OF EFFICACY AND OF SAFETY USING SELF-MONITORING OF DISEASE ACTIVITY VIA INTERNET PORTAL IN THE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS. **2018**, 8, 469-474
- 103 Clinical efficacy of the rituximab biosimilar Acellbia[®] 600 mg in patients with active rheumatoid arthritis in clinical practice. **2019**, 56, 703-708 1
- 102 Rheumatoide Arthritis [Internistische Aspekte. **2019**, 455-466
- 101 Clinical Ankle Involvement and Ultrasound Synovial Hypertrophy are Significant Predictors of DAS28-Defined Rheumatoid Arthritis Disease Activity. **2019**, 16, 19-33
- 100 Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis. **2019**, 13, 80-83
- 99 Should the Ultrasound of Hands be a Component of Rheumatoid Arthritis Remission Criteria?. **2019**, 15, 312-315 1
- 98 Evaluation of serum14-3-3 γ protein and Sema3A levels in rheumatoid arthritis: diagnostic and prognostic value. **2020**, 47,
- 97 Estimates of minimal clinically important improvements vary with the responsiveness of the sample. **2021**, 142, 110-118
- 96 Reexamination of the assessment criteria for rheumatoid arthritis disease activity based on comparison of the Disease Activity Score 28 with other simpler assessment methods. *Modern Rheumatology*, **2013**, 23, 260-8 3-3 2
- 95 Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly. *Modern Rheumatology*, **2013**, 23, 994-1000 3-3
- 94 Disability is the major negative predictor for achievement of Boolean-based remission in patients with rheumatoid arthritis treated with tocilizumab. *Modern Rheumatology*, **2013**, 23, 1205-10 3-3 6
- 93 Serum Levels of Beta-2 Microglobulin in Rheumatoid Arthritis Patients and its Relationship with Disease Activity: Can it be used as a Disease Activity Marker?. **2021**, 46, 297-304 1
- 92 Towards a universal definition of disease activity score thresholds: The AS135 score (Preprint).
- 91 Towards a universal definition of disease activity score thresholds: The AS135 score (Preprint).
- 90 Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid Arthritis. **2013**, 6, 126-36 2

89	Meridian-sinew release therapy for the treatment of refractory rheumatoid arthritis. 2015 , 8, 8485-96		
88	[Depression and anxiety in patients with psoriatic arthritis: Prevalence and associated factors]. 2020 , 52, 1048-1055		1
87	Association of Serum and Crevicular Fluid Dickkopf-1 Levels with Disease Activity and Periodontitis in Patients with Early Rheumatoid Arthritis. 2021 ,		0
86	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight-Joint Disease Activity Score, C-Reactive Protein Level, and Patient Global Assessment. 2021 ,		2
85	Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eight-joint Disease Activity Score, C-reactive protein level and patient global assessment. <i>RMD Open</i> , 2021 , 7,	5.9	1
84	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight-Joint Disease Activity Score, C-Reactive Protein Level, and Patient Global Assessment. 2021 ,		0
83	Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population. 2021 , 15, 463-470		0
82	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight-Joint Disease Activity Score, C-Reactive Protein Level, and Patient Global Assessment. 2021 ,		1
81	Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
80	Osteosarcopenia synergistically increases the risk of falls in patients with rheumatoid arthritis.. 2021 , 7, 140-145		0
79	A new tool to assess the quality of life of patients with rheumatoid arthritis that does not require a license: the QOL-RA II (Quality Of Life-Rheumatoid Arthritis Scale-II) questionnaire. 2019 , 16-21		
78	The Depression is a major determinant of functional capacity in patients with rheumatoid arthritis, regardless of disease activity. 2019 , 5-10		1
77	Level of stress, measured through the Perceived Stress Scale (EEP-10), and its association with disease activity in patients with Rheumatoid Arthritis. 2019 , 10-13		
76	Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.. 2022 , 386, 316-326		58
75	Ultrasound-detected tenosynovitis as a risk factor for flares in rheumatoid arthritis patients in clinical remission.. 2022 , 1		
74	Analytical and clinical evaluation of DiaSorin Liaison [®] Calprotectin fecal assay adapted for serum samples.. 2022 , e24258		1
73	Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach.. 2021 , 14, 1463-1471		3
72	Early Undifferentiated Arthritis: A Developing Country Perspective from Nepal. 2018 , 56, 983-990		

71	Sleep quality in rheumatoid arthritis. 2022 , 17, 34			○
70	Functionality assessment in patients with rheumatic diseases undergoing treatment in the Public Health System.. 2022 , 20, eAO6453			
69	Development of a natural language processing system for extracting rheumatoid arthritis outcomes from clinical notes using the national RISE registry.. 2022 ,			○
68	Assessment of Rheumatoid Hand Function as a Characteristic Feature of Rheumatoid Arthritis in Patients Treated with Methotrexate or Methotrexate with Biological Agents with and without Deformation of Hands.. 2022 ,			
67	Prevalence of depressive symptoms in patients with rheumatoid arthritis at a regional hospital in KwaZulu-Natal, South Africa.. 2022 , 28, 1702			
66	Association between Hematological Indices and Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks.. 2022 , 58,			○
65	Hydroxychloroquine non-availability during COVID-19 pandemic and its relation to anxiety level and disease activity in rheumatoid arthritis and lupus patients: a cross-sectional study. 2022 , 49,			
64	Towards a Better Implementation of Treat-to-Target Strategy in Rheumatoid Arthritis: A Comparison of Two Real-World Cohorts.. 2022 , 1			○
63	Impact of Tofacitinib on Components of the ACR Response Criteria: Posthoc Analysis of Phase III and Phase IIIb/IV Trials.. <i>Journal of Rheumatology</i> , 2022 ,	4.1		○
62	Suicide Risk in Rheumatoid Arthritis Patients is Associated With Suboptimal Vitamin D Levels.. <i>Journal of Clinical Rheumatology</i> , 2022 , 28,	1.1		1
61	Influence of frailty on patient global assessment in rheumatoid arthritis.. 2022 ,			
60	Aberrant functional connectivity between anterior cingulate cortex and left insula in association with therapeutic response to biologics in inflammatory arthritis.. 2022 , 55, 151994			○
59	SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis.. 2021 , 11,			○
58	The angiotensin-like protein 4, apolipoprotein C3, and lipoprotein lipase axis is disrupted in patients with rheumatoid arthritis.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 99	5.7		1
57	Musculoskeletal ultrasound may narrow the gap between patients and physicians in the assessment of rheumatoid arthritis disease activity.. <i>Rheumatology</i> , 2022 ,	3.9		
56	Early response to JAK inhibitors on central sensitization and pain catastrophizing in patients with active rheumatoid arthritis.. 2022 , 1			○
55	The value of ultrasound and magnetic resonance imaging scoring systems in explaining handgrip strength and functional impairment in rheumatoid arthritis patients: a pilot study.. 2022 , 1			
54	Impact of Treat-to-Target Therapy on Bone Mineral Density Loss in Patients With Rheumatoid Arthritis: A Prospective Cohort Study. <i>Frontiers in Endocrinology</i> , 2022 , 13,	5.7		○

53	Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study. <i>Reumatologia</i> , 2022 , 60, 81-91	1.7	
52	Dynamics of corticocortical brain functional connectivity relevant to therapeutic response to biologics in inflammatory arthritis.		
51	Apolipoprotein C-III is linked to the insulin resistance and beta-cell dysfunction that are present in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2022 , 24,	5.7	
50	Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response. <i>Annals of the Rheumatic Diseases</i> , annrheumdis-2022-222517	2.4	○
49	Predictors of Remission and Low Disease Activity in Rheumatoid Arthritis Patients. <i>Journal of Clinical Rheumatology</i> , Publish Ahead of Print,	1.1	
48	Evaluation of the adipokine profile (adiponectin, resistin, adipon, vaspin, and leptin) in patients with early rheumatoid arthritis and its correlation with disease activity. <i>Reumatologia</i> , 2022 , 60, 192-199	1.7	1
47	Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) Versus ASDAS: A Post Hoc Analysis of a Randomized Controlled Trial. <i>Journal of Rheumatology</i> , jrheum.211075	4.1	○
46	Assessment of inflammation in patients with rheumatoid arthritis using thermography and machine learning: a fast and automated technique. <i>RMD Open</i> , 2022 , 8, e002458	5.9	1
45	Effectiveness and safety of allergen immunotherapy in patients with allergic rhinitis complicated by rheumatic autoimmune diseases: a case series study. <i>Allergy, Asthma and Clinical Immunology</i> , 2022 , 18,	3.2	○
44	Safety and Effectiveness of Certolizumab Pegol in Japanese Patients with Rheumatoid Arthritis: Results from a 24-Week Post-Marketing Surveillance Study. <i>Modern Rheumatology</i> ,	3.3	○
43	Is It Good to Simplify Clinimetry in Chronic Inflammatory Joint Diseases?. <i>Journal of Rheumatology</i> , jrheum.220543		
42	Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis disease activity indicators: a systematic review and meta-analysis of randomized placebo-controlled trials. 1-15		3
41	Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy. 2022 , 24,		○
40	-Omic Approaches and Treatment Response in Rheumatoid Arthritis. 2022 , 14, 1648		○
39	Development and validation of equations for conversion from DAS28ESR and DAS28CRP to the SDAI in patients with rheumatoid arthritis.		
38	Interleukin 1 receptor antagonist relation to cardiovascular disease risk in patients with rheumatoid arthritis. 2022 , 12,		○
37	Immune checkpoint inhibitor-associated arthritis in advanced pulmonary adenocarcinoma: A case report. 10, 10701-10707		○
36	Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional study. 2022 , 14, 1759720X2211141		○

- 35 The association of depression and anxiety with treatment outcomes in patients with rheumatoid arthritis: A pooled analysis of five randomised controlled trials. **2022**, 14, 1759720X2211116 ○
- 34 Portuguese adaptation and validation of a patient-reported experience measure for patients with rheumatoid arthritis: A protocol study. **2022**, 7, e192 ○
- 33 Remission or Not Remission, That's the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis. ○
- 32 Analysis of Ana/Dfs70 Pattern in a Large Cohort of Autoimmune/Autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated from Colombia. **2022**, 12, 2181 ○
- 31 Refractory Inflammatory Arthritis definition and model generated through patient and multi-disciplinary professional modified Delphi process. ○
- 30 Factors That Influence Sleep Disturbance and the Mediating Effects of Depression on Sleep Disturbance in Patients With Rheumatoid Arthritis. **2022**, 41, 335-344 ○
- 29 American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. ard-2022-223413 1
- 28 Real-world effectiveness and safety of tofacitinib and abatacept in patients with rheumatoid arthritis. ○
- 27 American College of Rheumatology/ EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision. ○
- 26 Total Hip Arthroplasty in the Treatment of Inflammatory Arthritis. **2022**, 127-142 ○
- 25 Patient and physician global assessments of disease status in systemic sclerosis. ○
- 24 Treatment response to tumor necrosis factor inhibitors and methotrexate monotherapy in adults with juvenile idiopathic arthritis: Data from NORDMARD. jrheum.220645 ○
- 23 Prevalence of rheumatoid arthritis and diagnostic validity of a prediction score, in patients visiting orthopedic clinics in the Madinah region of Saudi Arabia: a retrospective cross-sectional study. 10, e14362 ○
- 22 Identification of SNPs associated with methotrexate treatment outcomes in patients with early rheumatoid arthritis. 13, ○
- 21 Using the derived 28-joint disease activity score patient-reported components (DAS28-P) index as a discriminatory measure of response to disease-modifying anti-rheumatic drug therapy in early rheumatoid arthritis. **2022**, 6, ○
- 20 Relation of some clinical composite indices of disease activity in rheumatoid arthritis to a simplified 12 joint power Doppler ultrasound activity index. **2023**, 45, 81-85 ○
- 19 Vatari guggulu and mahaushadhi kwatha in amavata (Rheumatoid Arthritis): An open-label, single-arm clinical study. **2022**, 16, 280 ○
- 18 A Thermographic Disease Activity Index for remote assessment of rheumatoid arthritis. **2022**, 8, e002615 ○

- 17 Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort. **2022**, 58, 1851 ○
- 16 A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis. **2022**, 6, ○
- 15 Relationship between Kinesiophobia, Foot Pain and Foot Function, and Disease Activity in Patients with Rheumatoid Arthritis: A Cross-Sectional Study. **2023**, 59, 147 ○
- 14 Dynamic Characteristics and Predictive Profile of Glucocorticoids Withdrawal in Rheumatoid Arthritis Patients Commencing Glucocorticoids with csDMARD: A Real-World Experience. ○
- 13 Association between Novel Hematological Indices and Measures of Disease Activity in Patients with Rheumatoid Arthritis. **2023**, 59, 117 ○
- 12 Clinical and psychological characteristics associated with negative beliefs and concerns about treatment necessity in rheumatic diseases. **2022**, 12, ○
- 11 Disease Activity Is More Associated with IL-1 Than with IL-6 in Patients with Rheumatoid Arthritis. **2023**, 13, 82 ○
- 10 The Use of Biological Agents in the Treatment of Rheumatoid Arthritis. **2007**, 36, 128-134 2
- 9 An efficient weighted network centrality approach for exploring mechanisms of action of the Ruellia herbal formula for treating rheumatoid arthritis. **2023**, 8, ○
- 8 Efficacy of personalized exercise program on physical function in elderly patients with rheumatoid arthritis at high risk for sarcopenia: study protocol for a randomized controlled trial. **2023**, 24, ○
- 7 Serum amyloid a level and musculoskeletal ultrasound in assessment of disease activity in rheumatoid arthritis patients. **2023**, 45, 153-158 ○
- 6 Efficacy and gastrointestinal tolerability of methotrexate in late-onset rheumatoid arthritis patients: a prospective cohort study. **2023**, 50, ○
- 5 Assessment of Rheumatoid Arthritis in Clinical Care. **2010**, 25, 1-11 ○
- 4 Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial. **2023**, 5, e215-e224 ○
- 3 Comprehensive evaluation of the influence of sex differences on composite disease activity indices for rheumatoid arthritis: results from a nationwide observational cohort study. **2023**, 7, ○
- 2 Lifestyle and body composition changes in patients with rheumatoid arthritis during the COVID-19 pandemic: A retrospective, observational study. **2023**, 9, 32-37 ○
- 1 Management of Rheumatoid Arthritis With a Digital Health Application. **2023**, 6, e238343 ○